Recent Updates
Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

Lixte Biotechnology Holdings, Inc.

35 indications, side-by-side phase, drug & LoA

$6.19

-1.06 (-14.62%)

D 20Pipeline Score Richly Valued Biotech · Clinical
Market Cap
72.81 M
EPS
-1.12
P/E Ratio
-
Value Trade
1.66 M
SEC Financials
Q1 2026

  • Dilution Risk

    80%

  • R&D Expenses

    333.38 K

  • Operating CF

    -1.83 M

  • Total Assets

    10.87 M

  • Total Liabilities

    1.69 M

  • Equity

    7.95 M

  • D/E Ratio

    12,345

8.09 %
Week
65.87 %
1 Month
86.67 %
3 Month
31.84 %
6 Month
-78.92 %
5 Year
-90.3 %
All Time
Cash Data
Distressed

  • Cash Position

    3.25 M

  • Monthly Burn

    610.00 K

  • Runway

    4.4 mo

  • Burn Trend

    Accelerating

  • SEC Filing

    May 14, 2026
Overview
Volume
871.82 K
52 Week Range
0.64 - 6.26
% held by Insiders
6.14 %
% held by Institutions
4.21 %
Enterprise Value
71.85 M
Total Shares
11.62 M
Short %
2.13 %
Float Shares
11.61 M
Company Description
HQ: 433 PLAZA REAL, BOCA RATON, FL...
Employees:3
https://www.lixte.com

locked

Upcoming Catalyst
Catalyst Drug/Treatment Stage Probability of Approval Description Drug Type Therapeutic Area Source
Phase 1b/2 Data readout example
LB-100 Ovarian clear cell cancer
Phase 1B/2
—
Small Molecules
Oncology
LB-100 Ovarian clear cell cancer
Phase 1B/2
—
Small Molecules
Oncology
LB-100 Ovarian clear cell cancer
Phase 1B/2
—
Small Molecules
Oncology
Unlock Upcoming Catalyst data
Drug Pipeline Intelligence
D20
Pipeline Score
$0M
Pipeline Value
Richly Valued
Valuation Signal
1
Drugs Scored
0.0x
rNPV / MCap
Top 19%
Micro Cap
(rank 734 of 905)
Percentile Rank
Lixte Biotechnology Holdings, Inc. faces pipeline headwinds (20/100), with $47M risk-adjusted pipeline value, led by LB-100 in Tumors (Phase 1), but cash runway is a concern.
Showing 1 of 1 assets
DrugIndicationPhaseNCT IDPTRSrNPVStatusEnrollmentVelocityDesignCompletionML SignalLast Change
LB-100
Small molecule		Myelodysplastic SyndromesPhase 1NCT0388666222% $47M RECRUITING 47 STALLED F (17) Jul 1, 2021LOW_RISKLOW
May 26, 2026
Unlock Drug Pipeline Intelligence
Clinical Trial Results
Drug Name Indications Phase Date Trial Results Summary Title Source
Example Drug
Example indication for clinical evaluation
Phase 3
2025-12-01
Example Drug
Example indication for clinical evaluation
Phase 3
2025-12-01
Example Drug
Example indication for clinical evaluation
Phase 3
2025-12-01
Unlock Clinical Trial Results data
Inside Trades
TREND
CORPORATE INSIDERS BOUGHT SHARES WORTH 1.8M IN THE LAST 3 MONTHS
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Unlock Inside Trades data
Show Data
Hedge Funds
TREND
HEDGE FUNDS INCREASED HOLDINGS BY 200.0K SHARES IN THE LAST QUARTER
Shares Held
2040.00B1530.00B1020.00B510.00B0
Q3
2024
Q4
2024
Q1
2025
Q2
2025
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Fund Count
60%
Share Volume
25%
Conviction
15%
Hedge Funds invested in LIXT
HedgeFund Name
( 3 )
% of Portfolio Current MV
-
Shares Owned
-
Activity
Avg Price $0

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K
Unlock Hedge Funds table data
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
LIXT
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
LIXT
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
LIXT
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
Unlock Biotech Analyst Ratings data
LIXT Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
Unlock Price Target Trend
LIXT Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
ExpirationVolumeOpen InterestImplied Volatility CallsImplied Volatility Puts
CallsPutsPut-Call RatioCallsPutsPut-Call RatioIVOiWaIvVWaIvIVOiWaIvVWaIv
Unlock Option Chain Statistics data
Option Chain
CallsStrikePuts
Last PriceVolumeOpen InterestLast PriceVolumeOpen Interest
No data available
Unlock Option Chain data
Unlock Options Chart data
Open interest
0 600K 1.2M 1.8M Avg OI 1.00 M Open Interest
0 1 2 3 1.1 Put-Call Ratio
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
0 450K 900K 1.4M Avg OV 750.00 K Option Volume
0 1 2 3 0.95 Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Latest Lixte Biotechnology Holdings, Inc. (LIXT) News & Alerts
-
Sunday, June 14, 2026
(%)
+ More

Demo Biotech Announces Positive Phase 3 Results

Competitive Position
How LIXT ranks across every disease it competes in
Indication Rank Phase Best DrugTop 3 Competitors Market $B LoA Position
Myelodysplastic Syndromes #27 of 33 PHASE 1 LB-100
BMY ABBV TAK
$2.5B 0.95 FOLLOWER